Table 3.
Baseline Characteristics by MACE (N = 252)
| No MACE (n = 222) | MACE (n = 30) | p Value | |
|---|---|---|---|
| Age at start of treatment, yrs | 69.1 ± 10.1 | 67.2 ± 12.5 | 0.34 |
| Female | 99 (44.6) | 13 (43.3) | 1.00 |
| Body mass index, kg/m2 | 25.2 ± 5.4 | 24.8 ± 5.5 | 0.74 |
| Cardiovascular risk factors | |||
| Current or prior smoking | 187 (84.2) | 26 (86.7) | 1.00 |
| Hypertension | 151 (68.0) | 21 (70.0) | 1.00 |
| Diabetes mellitus | 63 (28.4) | 10 (33.3) | 0.67 |
| Pre-treatment comorbidities | |||
| Coronary artery disease | 55 (24.8) | 12 (40.0) | 0.08 |
| Prior myocardial infarction | 15 (6.8) | 3 (10.0) | 0.46 |
| Prior coronary stenting | 20 (9.0) | 2 (6.7) | 1.00 |
| Coronary artery bypass graft | 20 (9.0) | 2 (6.7) | 1.00 |
| Stroke | 14 (6.3) | 2 (6.7) | 1.00 |
| Heart failure | 17 (7.7) | 3 (10.0) | 0.72 |
| Chronic obstructive pulmonary disease | 90 (40.5) | 12 (40.0) | 1.00 |
| Chronic kidney disease∗ | 24 (10.8) | 6 (20.0) | 0.14 |
| Baseline left ventricular ejection fraction† | 58.9 ± 8.4 | 60.3 ± 9.1 | 0.86 |
| Pre-treatment cardiovascular medications | |||
| Aspirin | 72 (32.4) | 15 (50.0) | 0.07 |
| Statin | 95 (42.8) | 15 (50.0) | 0.56 |
| Beta-blockers | 83 (37.4) | 14 (46.7) | 0.33 |
| ACE inhibitor or ARB | 66 (29.7) | 6 (20.0) | 0.39 |
| Aldosterone receptor antagonist | 4 (1.8) | 2 (6.7) | 0.15 |
| Primary lung cancer type | |||
| Non–small-cell lung cancer | 172 (77.5) | 27 (90.0) | 0.15 |
| Small-cell lung cancer | 50 (22.5) | 3 (10.0) | |
| Prior or concurrent chemotherapy or radiation | |||
| Chemotherapy‡ | 200 (90.1) | 27 (90.0) | 1.00 |
| Radiation | 137 (61.7) | 21 (70.0) | 0.43 |
| Thoracic radiation | 103 (46.4) | 9 (30.0) | 0.12 |
| Thoracic radiation dose, Gy | 23.7 ± 28.8 | 17 ± 30.6 | 0.63 |
| Vascular endothelial growth factor or tyrosine kinase inhibitors§ | 45 (20.3) | 7 (23.3) | 0.64 |
Values are mean ± SD or n (%).
Abbreviations as in Table 1.
∗
Chronic kidney disease = glomerular filtration rate <60 ml/min/1.73 m2.
†
Baseline echocardiography available in 47 of 117 non-ICI– and 46 of 135 ICI-treated patients.
‡
Chemotherapy agents consisted of, decreasing frequency: carboplatin, pemetrexed, paclitaxel, etoposide, cisplatin, gemcitabine, docetaxel, and vinorelbine.
§
VEGFI and TKI agents consisted of, in decreasing frequency: bevacizumab, erlotinib, and afatinib.